Urgent.News

600+ sources. One page. See who else covered it.

Editions

Finance & Markets

Otsuka succeeds with kidney drug; BioNTech downgrades revenue projection

✅ Otsuka’s confirmatory kidney disease data: The drugmaker said Voyxact met a key secondary endpoint in the Phase 3 VISIONARY study in patients with IgA nephropathy (IgAN). The treatment increased the ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Finance & Markets

More from Tuesday 4 August →